Measuring productivity loss in early relapsing-remitting multiple sclerosis

Maza, Susana Sainz de la; Mauriño, Jorge; Borges, Marcos R. S.; Martín-Martínez, Jesús; Sotoca, Javier; Alonso, Ana; Caminero, Ana B.; Borrega, Laura; Menoyo, José Luis Sánchez; Hernández, Francisco Javier Barrero; Calles, Carmen; Brieva, Luís; Blasco, María Rosario; García‐Soto, Julio Dotor; Campo-Amigo, María del; Navarro-Cantó, Laura; Agüera, Eduardo; Garcés, Moisès; Carmona, Olga; Gabaldón-Torres, Laura; Forero, Lucía; Hervás, Mariona; Alda, Lucía Ruiz de; Gómez-Ballesteros, Rocío; Castillo-Triviño, Tamara

doi:10.1016/j.msard.2021.103398

Cited by 8 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among 929 Australians with MS, those with any comorbidity averaged 1.2 days more lost productivity in the preceding four weeks than individuals without comorbidity ( 70 ). Similarly, a study among individuals diagnosed with MS within the last three years, found anxiety and depression were associated with both presenteeism and absenteeism ( 71 ).…”

Section: Effects Of Comorbiditiesmentioning

confidence: 96%

Etiology, effects and management of comorbidities in multiple sclerosis: recent advances

Marrie

Fisk

Fitzgerald³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Comorbid conditions commonly affect people with multiple sclerosis (MS). Population-based studies indicate that people with MS have an increased incidence of ischemic heart disease, cerebrovascular disease, peripheral vascular disease, and psychiatric disorders as compared to people without MS. People with MS from underrepresented minority and immigrant groups have higher comorbidity burdens. Comorbidities exert effects throughout the disease course, from symptom onset through diagnosis to the end of life. At the individual level, comorbidity is associated with higher relapse rates, greater physical and cognitive impairments, lower health-related quality of life, and increased mortality. At the level of the health system and society, comorbidity is associated with increased health care utilization, costs and work impairment. A nascent literature suggests that MS affects outcomes from comorbidities. Comorbidity management needs to be integrated into MS care, and this would be facilitated by determining optimal models of care.

show abstract

Section: Effects Of Comorbiditiesmentioning

confidence: 96%

Etiology, effects and management of comorbidities in multiple sclerosis: recent advances

Marrie

Fisk

Fitzgerald³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…We found a significant effect of response type (dilation vs. constriction) on PRS. 4 Moreover, we showed that PRS (regardless of response type) decreases as a function of time on task in pwMS only and especially in the HCL condition. Autonomic disturbance is frequent in MS 48 , and corresponds to a blunted parasympathetic drive 16,17 .…”

Section: Discussionmentioning

confidence: 66%

“…Fatigue is highly prevalent in multiple sclerosis (MS) 1,2 and about two thirds of patients consider it as one of their worst symptoms 3 . Fatigue alters quality of life, and jeopardizes employment and occupational status 4,5 . Cognitive and motor fatigue are considered as distinct entities 6,7 , with the former corresponding to a sensation of mental exhaustion, and pwMS can report one or the two.…”

Section: Introductionmentioning

confidence: 99%

Pupil response speed as a marker of cognitive fatigue in early Multiple Sclerosis☆

Guillemin

Hammad

Read

et al. 2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

“…Its unpredictable symptoms, like fatigue, impair mobility and quality of life and cognitive dysfunction posing burdens on individuals, families, and healthcare systems ( 1 , 2 ). It is the most common cause of non-traumatic disability in young and middle-aged adults ( 3 , 4 ). MS is characterized by neurodegeneration caused by axonal injury, present from the early disease stages ( 5 , 6 ).…”

Section: Introductionmentioning

confidence: 99%

Value contribution of blood-based neurofilament light chain as a biomarker in multiple sclerosis using multi-criteria decision analysis

Monreal,

Ruiz,

San Román

et al. 2024

Front. Public Health

Self Cite

View full text Add to dashboard Cite

IntroductionMultiple sclerosis (MS) is a chronic autoimmune demyelinating disease that represents a leading cause of non-traumatic disability among young and middle-aged adults. MS is characterized by neurodegeneration caused by axonal injury. Current clinical and radiological markers often lack the sensitivity and specificity required to detect inflammatory activity and neurodegeneration, highlighting the need for better approaches. After neuronal injury, neurofilament light chains (NfL) are released into the cerebrospinal fluid, and eventually into blood. Thus, blood-based NfL could be used as a potential biomarker for inflammatory activity, neurodegeneration, and treatment response in MS. The objective of this study was to determine the value contribution of blood-based NfL as a biomarker in MS in Spain using the Multi-Criteria Decision Analysis (MCDA) methodology.Materials and methodsA literature review was performed, and the results were synthesized in the evidence matrix following the criteria included in the MCDA framework. The study was conducted by a multidisciplinary group of six experts. Participants were trained in MCDA and scored the evidence matrix. Results were analyzed and discussed in a group meeting through reflective MCDA discussion methodology.ResultsMS was considered a severe condition as it is associated with significant disability. There are unmet needs in MS as a disease, but also in terms of biomarkers since no blood biomarker is available in clinical practice to determine disease activity, prognostic assessment, and response to treatment. The results of the present study suggest that quantification of blood-based NfL may represent a safe option to determine inflammation, neurodegeneration, and response to treatments in clinical practice, as well as to complement data to improve the sensitivity of the diagnosis. Participants considered that blood-based NfL could result in a lower use of expensive tests such as magnetic resonance imaging scans and could provide cost-savings by avoiding ineffective treatments. Lower indirect costs could also be expected due to a lower impact of disability consequences. Overall, blood-based NfL measurement is supported by high-quality evidence.ConclusionBased on MCDA methodology and the experience of a multidisciplinary group of six stakeholders, blood-based NfL measurement might represent a high-value-option for the management of MS in Spain.

show abstract

Measuring productivity loss in early relapsing-remitting multiple sclerosis

Cited by 8 publications

References 35 publications

Etiology, effects and management of comorbidities in multiple sclerosis: recent advances

Etiology, effects and management of comorbidities in multiple sclerosis: recent advances

Pupil response speed as a marker of cognitive fatigue in early Multiple Sclerosis☆

Value contribution of blood-based neurofilament light chain as a biomarker in multiple sclerosis using multi-criteria decision analysis

Contact Info

Product

Resources

About